In the Media

September 21, 2021

How the scalability of rare cannabinoids makes them more affordable

In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.

Read the article and watch the full video at The Dales Report.

Source: The Dales Report

Share this post

Latest Articles

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s

September 4, 2024

Article in Fierce Biotech: The Evolving Alzheimer’s Disease Landscape

There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development

August 26, 2024

What is Neuritogenesis? How does Neuritogenesis Affect Alzheimer’s Disease?

In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.

August 16, 2024